FLT3 and acute myeloid leukemia: A follow-up phase I/II multicenter, randomized dose-ranging and expansion study of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML will attempt to identify the optimal doses of these agents when given in combination (NCT05520567).